<- Go home

Added to YB: 2026-08-11

Pitch date: 2026-08-07

NOVO-B.CO [neutral]

Novo Nordisk A/S

+1.55%

current return

Author Info

No bio for this author

Company Info

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.

Market Cap

DKK 1.3T

Pitch Price

DKK 47.00

Price Target

N/A

Dividend

3.83%

EV/EBITDA

8.24

P/E

11.65

EV/Sales

4.39

Sector

Pharmaceuticals

Category

growth

Show full summary:
Theodosian Capital | Stocks Update 7/8/2026 - NOVOB – Rare good news

NOVO-B.CO (earnings): Q2 reported sales +3% CER (+7% adj); reported op profit -16% (hit by prior-yr one-offs + DKK6.3bn impairment), adj op profit +11% CER. Wegovy rollouts in UAE/UK show encouraging uptake. FY guide raised to 0% to -6% (from -4% to -12%). 13.5x 2028 EPS, 3.9% yield.

Read full article (1 min)